Evidence map›Paper›PMID 39860250›Full record

ArticleMolecules (Basel, Switzerland)2025

Two Cysteines in Raf Kinase Inhibitor Protein Make Differential Contributions to Structural Dynamics In Vitro.

Hyun Sang Cho, Mohammad Faysal Al Mazid, Eun-Young Lee, Md Abu Rayhan, Hyoun Sook Kim, Byung Il Lee, Hye Jin You

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hyun Sang ChoCancer Microenvironment Branch, Division of Cancer Biology, Research Institute, National Cancer Center, Goyang-si 10408, Republic of Korea.ORCID 0009-0001-0089-5583
Mohammad Faysal Al MazidDepartment of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang-si 10408, Republic of Korea.ORCID 0000-0002-1311-5611
Eun-Young LeeCancer Microenvironment Branch, Division of Cancer Biology, Research Institute, National Cancer Center, Goyang-si 10408, Republic of Korea.ORCID 0000-0001-7295-8574
Md Abu RayhanDepartment of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang-si 10408, Republic of Korea.ORCID 0000-0002-3660-1639
Hyoun Sook KimTargeted Therapy Branch, Division of Precision Medicine, Research Institute, National Cancer Center, Goyang-si 10408, Republic of Korea.ORCID 0000-0003-1095-6463
Byung Il LeeDepartment of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang-si 10408, Republic of Korea.ORCID 0000-0003-1270-8439
Hye Jin YouCancer Microenvironment Branch, Division of Cancer Biology, Research Institute, National Cancer Center, Goyang-si 10408, Republic of Korea.ORCID 0000-0001-5566-5171

Funding

National Cancer Center NCC-2410760 (to H.J.Y.)National Cancer Center NCC-2410861 (to H.J.Y.)National Research Foundation of Korea No. 2021R1A2C2014147 to H.J.Y.
6 · The paper itself

Abstract

As a scaffolding protein, Raf kinase binding protein (RKIP) is involved in a variety of cellular pathways, including the Raf-MEK-ERK-cascade. It acts as a negative regulator by binding to its partners, making it an attractive target in the development of therapeutic strategies for cancer. Despite its structural stability as a monomer, RKIP may form a dimer, resulting in the switching of binding partners. It is still unclear how RKIP switches between monomeric and dimeric forms. Here, we identified the role of cysteine 133 in RKIP structural dynamics using recombinant human RKIP (rhRKIP) proteins purified from

Indexed as

CysteinePhosphatidylethanolamine Binding ProteinAmino Acid SequenceCell Line, TumorCell SurvivalEscherichia coliHumansProtein BindingProtein MultimerizationRecombinant ProteinsTandem Mass SpectrometryCysteinePEBP1 protein, humanPhosphatidylethanolamine Binding ProteinRecombinant ProteinscancercysteinedimerizationRaf kinase inhibitor protein

Identifiers

PMID39860250
PMCPMC11767649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.